Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Petra Kozma"'
Autor:
Niral Karia, Petra Kozma-Wiebe, Niall Patton, Joachim Wachtlin, Nishal Patel, Theodor Stappler, David H. W. Steel, Thomas Raber, Hans Hoerauf
Publikováno v:
Retina. 41:266-276
Purpose Randomized clinical trials have demonstrated the safety and efficacy of ocriplasmin in patients with vitreomacular traction (VMT), including those with macular hole (MH). The INJECT study prospectively evaluated ocriplasmin in the setting of
Publikováno v:
Retina (Philadelphia, Pa.)
The MP-1 substudy of the OASIS trial evaluated the effects of ocriplasmin and symptomatic VMA resolution on visual fixation and macular sensitivity using microperimetry, identifying parameters that were distinct between patients with and without VMA
Autor:
Arshad M. Khanani, Mitchell S. Fineman, Kimberly A Drenser, Joseph M Gunn, Daniel F. Rosberger, Dante J. Pieramici, Luc Duchateau, Petra Kozma
Publikováno v:
CLINICAL OPHTHALMOLOGY
Clinical Ophthalmology (Auckland, N.Z.)
Clinical Ophthalmology (Auckland, N.Z.)
Kimberly A Drenser,1 Dante J Pieramici,2,3 Joseph M Gunn,4 Daniel F Rosberger,5 Petra Kozma,6 Mitchell S Fineman,7,8 Luc Duchateau,9 Arshad M Khanani10 1Associated Retinal Consultants P.C., Royal Oak, MI, USA; 2California Retina Consultants, Santa Ba
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1bac82c0029528a2ddd06ea8bb09752b
https://biblio.ugent.be/publication/8740216/file/8740217
https://biblio.ugent.be/publication/8740216/file/8740217
Autor:
Robert C. Sergott, Matthew S. Benz, Andrew N. Antoszyk, Petra Kozma, David G. Birch, Esmeralda Meunier, Joseph I Markoff, Daniel M. Miller
Publikováno v:
Retina. 38:364-378
PURPOSE To explore a possible association between full-field electroretinograms with vitreomacular adhesion resolution and best-corrected visual acuity as part of the prospective, randomized, double-masked, sham-controlled Ocriplasmin for Treatment f
Publikováno v:
Expert Review of Ophthalmology. 11:247-258
Introduction: Ocriplasmin is the first pharmacologic treatment approved for vitreomacular adhesion/traction. Much is still unknown about this new enzymatic vitreolysis treatment and this review article explores the clinical trial data available on th
Autor:
Mathew MacCumber, David S. Boyer, Jay S. Duker, Petra Kozma, Dante J. Pieramici, Daniel F. Rosberger, Peter K. Kaiser, Brian C Joondeph, Jeffrey S. Heier, Arshad M. Khanani
Publikováno v:
Ophthalmology. Retina. 3(1)
Purpose To evaluate clinical outcomes and safety up to 12 months after ocriplasmin injection for the treatment of patients with symptomatic vitreomacular adhesion (VMA)/vitreomacular traction (VMT) in a real-world setting. Design The Phase IV Ocripla
Publikováno v:
Ophthalmology. 123(10)
Purpose The Ocriplasmin for Treatment for Symptomatic Vitreomacular Adhesion Including Macular Hole (OASIS) trial was designed to evaluate the long-term efficacy and safety profile of ocriplasmin for the treatment of symptomatic vitreomacular adhesio